Biochemistry and Molecular Genetics Department, Hospital Clínic, Barcelona, Spain.
Gastroenterology Department, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona, Barcelona, Spain.
Gastroenterology. 2014 Sep;147(3):628-636.e1. doi: 10.1053/j.gastro.2014.06.008. Epub 2014 Jun 14.
BACKGROUND & AIMS: The latest generation of fecal immunochemical tests (FIT) allows for quantitation of hemoglobin in feces, allowing for selection of optimal cut-off concentrations. We investigated whether individuals with positive results from quantitative FITs, in combination with other factors, could be identified as being at greatest risk for advanced colorectal neoplasia.
In a retrospective study, we analyzed data from a consecutive series of 3109 participants with positive results from FITs (≥20 μg/g of feces) included in the first round of the Barcelona colorectal cancer screening program, from December 2009 through February 2012. All participants underwent colonoscopy and were assigned to groups with any advanced colorectal neoplasia or with nonadvanced colorectal neoplasia (but with another diagnosis or normal examination findings).
Median fecal hemoglobin concentrations were significantly higher in participants with advanced colorectal neoplasia (105 μg/g; interquartile range, 38-288 μg/g) compared with participants with nonadvanced colorectal neoplasia (47 μg/g; interquartile range, 23-119 μg/g) (P < .001). Positive predictive values for advanced colorectal neoplasia, determined using arbitrary fecal hemoglobin concentrations, differed with sex and age. Multivariate logistic regression analysis identified sex (men: odds ratio [OR], 2.07; 95% confidence interval, 1.78-2.41), age (60-69 y: OR, 1.24; 95% confidence interval, 1.07-1.44), and fecal hemoglobin concentration (>177 μg/g: OR, 3.80; 95% confidence interval, 3.07-4.71) as independent predictive factors for advanced colorectal neoplasia. Combining these factors, we identified 16 risk categories associated with different probabilities of identifying advanced colorectal neoplasia. Risk for advanced colorectal neoplasia increased 11.46-fold among individuals in the highest category compared with the lowest category; positive predictive values ranged from 21.3% to 75.6%.
Fecal hemoglobin concentration, in addition to sex and age, in individuals with positive results from FITs can be used to stratify probability for the detection of advanced colorectal neoplasia. These factors should be used to prioritize individuals for colonoscopy examination.
最新一代粪便免疫化学检测(FIT)可定量检测粪便中的血红蛋白,从而选择最佳的截断浓度。我们研究了定量 FIT 阳性者结合其他因素是否可识别为结直肠高级别肿瘤的高危人群。
在一项回顾性研究中,我们分析了 2009 年 12 月至 2012 年 2 月参加巴塞罗那结直肠癌筛查项目第一轮的 3109 例 FIT 阳性(粪便中血红蛋白≥20μg/g)患者的数据。所有患者均行结肠镜检查,并分为存在任何高级别结直肠肿瘤或存在非高级别结直肠肿瘤(但存在其他诊断或正常检查结果)的两组。
与非高级别结直肠肿瘤患者(中位数 47μg/g;四分位距 23-119μg/g)相比,高级别结直肠肿瘤患者的粪便血红蛋白浓度中位数明显更高(105μg/g;四分位距 38-288μg/g)(P<0.001)。使用任意粪便血红蛋白浓度确定的高级别结直肠肿瘤阳性预测值因性别和年龄而异。多变量 logistic 回归分析确定了性别(男性:比值比 [OR],2.07;95%置信区间,1.78-2.41)、年龄(60-69 岁:OR,1.24;95%置信区间,1.07-1.44)和粪便血红蛋白浓度(>177μg/g:OR,3.80;95%置信区间,3.07-4.71)是高级别结直肠肿瘤的独立预测因素。结合这些因素,我们确定了 16 个与不同高级别结直肠肿瘤检出概率相关的风险类别。与最低风险类别相比,最高风险类别的个体发生高级别结直肠肿瘤的风险增加 11.46 倍;阳性预测值范围为 21.3%-75.6%。
在 FIT 阳性者中,除性别和年龄外,粪便血红蛋白浓度也可用于分层检测高级别结直肠肿瘤的概率。这些因素应用于优先安排结肠镜检查。